1. Home
  2. NVEE vs ARQT Comparison

NVEE vs ARQT Comparison

Compare NVEE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVEE
  • ARQT
  • Stock Information
  • Founded
  • NVEE 1949
  • ARQT 2016
  • Country
  • NVEE United States
  • ARQT United States
  • Employees
  • NVEE N/A
  • ARQT N/A
  • Industry
  • NVEE Other Consumer Services
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVEE Consumer Discretionary
  • ARQT Health Care
  • Exchange
  • NVEE Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • NVEE 1.5B
  • ARQT 1.7B
  • IPO Year
  • NVEE 2013
  • ARQT 2020
  • Fundamental
  • Price
  • NVEE $22.89
  • ARQT $14.38
  • Analyst Decision
  • NVEE Buy
  • ARQT Strong Buy
  • Analyst Count
  • NVEE 4
  • ARQT 7
  • Target Price
  • NVEE $26.50
  • ARQT $18.67
  • AVG Volume (30 Days)
  • NVEE 946.0K
  • ARQT 1.5M
  • Earning Date
  • NVEE 08-06-2025
  • ARQT 08-06-2025
  • Dividend Yield
  • NVEE N/A
  • ARQT N/A
  • EPS Growth
  • NVEE N/A
  • ARQT N/A
  • EPS
  • NVEE 0.45
  • ARQT N/A
  • Revenue
  • NVEE $962,752,000.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • NVEE $11.23
  • ARQT $61.01
  • Revenue Next Year
  • NVEE $5.16
  • ARQT $37.95
  • P/E Ratio
  • NVEE $49.71
  • ARQT N/A
  • Revenue Growth
  • NVEE 8.74
  • ARQT 100.03
  • 52 Week Low
  • NVEE $14.75
  • ARQT $7.86
  • 52 Week High
  • NVEE $26.14
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • NVEE 50.17
  • ARQT 47.80
  • Support Level
  • NVEE $21.77
  • ARQT $14.34
  • Resistance Level
  • NVEE $23.35
  • ARQT $15.38
  • Average True Range (ATR)
  • NVEE 0.43
  • ARQT 0.70
  • MACD
  • NVEE -0.11
  • ARQT -0.07
  • Stochastic Oscillator
  • NVEE 59.76
  • ARQT 17.43

About NVEE NV5 Global Inc.

NV5 Global Inc is a provider of technology, conformity assessment, and consulting solutions to public and private sector clients in the infrastructure, utility services, construction, real estate, environmental, and geospatial markets, operating nationwide and abroad. The Company's clients include the U.S. Federal, state and local governments, and the private sector. It also serve quasi-public and private sector clients from the education, healthcare, utility services, and public utilities, including schools, universities, hospitals, health care providers, and insurance providers. The operating business segments are Infrastructure, Building, Technology & Sciences, and Geospatial Solutions. The maximum revenue derives from the infrastructure segment.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: